Thermo Fisher Scientific, SHL Medical Collaborate on Integrated Drug-Device Solutions

Thermo Fisher Scientific Inc. is collaborating with SHL Medical to meet growing demand for drug delivery solutions. With an expansion of sterile fill-finish and autoinjector final assembly capacity at its Ridgefield, N.J., site, these investments create a fully integrated U.S.-based offering spanning sterile manufacturing, device assembly, and commercial packaging for drug-device combination products.

Demand for patient-centric, self-administered injectable therapies continues to grow across multiple therapeutic areas, including autoimmune diseases, inflammatory conditions, and other chronic diseases. To meet this need, Thermo Fisher is expanding pre-filled syringe (PFS) fill-finish and device assembly in Ridgefield. Concurrently, its strategic partnership with SHL Medical enables the integration of SHL Medical’s Molly autoinjector platform with Thermo Fisher’s sterile manufacturing network, thus creating a seamless, end-to-end solution from drug product to finished device.

“The collaboration with SHL Medical, a global leader in autoinjectors, and our expansion in Ridgefield are important steps in helping our customers meet growing demand,” said Michelle Logan, vice president, Drug Product – Steriles, North America, at Thermo Fisher. “By fully integrating fill-finish with device assembly, we can simplify supply chains, accelerate timelines, and ultimately support our customers in delivering critical therapies to patients more efficiently.”

Thermo Fisher acquired the Ridgefield facility from Sanofi in September 2025 as part of its strategy to strengthen its U.S. manufacturing footprint. The site is being developed as a North American hub for integrated sterile fill-finish, autoinjector final assembly and packaging, increasing domestic capacity to support customer supply chains.

Under the strategic, non-exclusive collaboration, Thermo Fisher and SHL Medical will provide integrated support for SHL Medical’s Molly autoinjector platform at the Ridgefield site, including device final assembly, packaging, and distribution. The collaboration aims to simplify development and manufacturing for pharmaceutical and biotechnology customers, supporting a streamlined path from drug product manufacturing through commercialization.

“This collaboration with Thermo Fisher represents a significant milestone for SHL Medical and for the customers we jointly serve,” SHL Medical Chief Growth Officer Markus Puusepp stated. “By combining SHL Medical’s proven Molly autoinjector platform and global device expertise with Thermo Fisher’s sterile fill-finish and commercial manufacturing capabilities, we are creating an integrated solution. This installation in Ridgefield underscores our shared commitment to supporting the growing demand for high-quality, patient-centric combination products and accelerating time to market for innovative therapies worldwide.”

The addition of autoinjector capabilities in Ridgefield complements Thermo Fisher’s global network, including sites in Allentown, Pa.; Horsham, U.K.; and planned capacity in Greenville, N.C., creating a scalable platform across development and commercial stages. Continued investments across its steriles network, including Greenville, N.C.; Ferentino, Italy; and expansion in APAC, further strengthen the company’s ability to support customers with integrated, global manufacturing solutions, executives claim.

Thermo Fisher Scientific Inc. serves science globally, with annual revenue of more than $40 billion. Whether its customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics, or developing and manufacturing life-changing therapies, the company supports them. Its global team delivers a combination of technologies, purchasing convenience, and pharmaceutical services through various brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.